9. Areas of Disagreement:
1.How
to screen (which tool)
2.When to screen
3.How often to screen
4.Which screening population
5.Who should screen
6.Does screening work
40. BOTH. How Many Receive Ps Help? (n=2557)
Proportion meta-analysis plot [random effects]
Kadan-Lottick et al (2005)
0.89 (0.77, 0.96)
Plass and Koch (2001)
0.60 (0.46, 0.72)
Siedentopf et al (2009)
0.46 (0.35, 0.58)
Fritsche et al (2004)
0.43 (0.28, 0.59)
Bogaarts et al (2011)
0.38 (0.27, 0.49)
Söllner et al (2004)
0.35 (0.26, 0.45)
Shimizu et al (2005)
0.28 (0.18, 0.41)
Shimizu et al (2009)
0.25 (0.18, 0.33)
Merckaert et al (2009)
0.21 (0.17, 0.25)
Morasso et al (2010)
0.16 (0.05, 0.33)
Sharpe et al (2004)
0.15 (0.10, 0.22)
McDowell et al (2010)
0.14 (0.11, 0.18)
combined
0.35 (0.25, 0.46)
0.0
0.2
0.4
0.6
proportion (95% confidence interval)
0.8
1.0
41. 12mo Service Use (NIH, 2002)
40
34.6
32.7
35
Cancer n=4878
No Cancer n=90,737
30
25
19.1
20
16.1
% Receiving Any treatment for Mental Health
14
15
10
11.7 11
7.2
5.7
6.3
5.7 5
6.4
5
8.9
7.7
6.5
6.2
3.9
5
2.3
3.2
1.8
75+
y ea
rs
6574
ear
s
4564
y
y ea
rs
1844
con
diti o
ns
hro
nic
me
di ca
l
3c
2c
hro
nic
me
di ca
l
con
diti o
ns
con
diti o
n
hro
nic
me
di ca
l
1c
con
d iti
No
c hr
o ni
cm
edi
cal
Me
n ta
l Ill
No
ons
Hea
l th
th
eal
Il l H
Me
nt a
l
Al l
P
atie
nt s
0
Maria Hewitt, Julia H. Rowland Mental Health Service Use Among Adult Cancer Survivors: Analyses of the National Health Interview Survey Journal of Clinical
Oncology, Vol 20, Issue 23 (December), 2002: 4581-4590
42.
43. Overall Effect of screening
Baseline CARE x =
35%
with screening
+10% (0-20%)
+ follow-up
+treatment
+10% (0-20%)
+10% (0-20%)
Screening Cancer Patients for Distress: What Does the Evidence from 31 Studies Actually Show?
Alex J Mitchell
University of Leicester, UK
Objectives
There is still considerable uncertainty about the merits of screening for distress in cancer settings. Screening is not widely implemented nationally, but this is only problematic if screening actually has benefits and few harms. Several narrative reviews have addressed this area but none to date have been able to quantative summarize what screening can and cannot achieve.
Method
A systematic search and meta-analysis of the latest data was conducted. 17 observational screening studies were identified that revealed how many patients received psychosocial care or referral following screening. 19 implementation studies were identified that clarified how many patients benefited from distress screening (or feedback of screening results). An additional 5 implementation studies examined quality of life, making a total of 31 distress/QoL studies. Outcomes were effects on patient wellbeing, quality of care and communication.
Results
7 of 14 of the screening RCTs reported benefits on patient wellbeing. 2 of 10 non-randomized sequential cohort screening studies reported benefits on patient wellbeing. Nine implementation studies measured receipt of psychosocial referral. The chances of receiving a psychosocial referral increased by 3x in cancer patients who were screened vs not screened, an increase of 12% over usual care (p = 0.03). Six QoL implementation studies found that screening significantly increased clinician-patient communication of emotional issues after exclusion of studies which omitted feedback of results to clinicians.
Barriers to screening were significant. The proportion of cancer patients who received psychosocial care after a positive distress screen was only 31.3% but this was 20% greater than those given resources after a negative screen. Screening was more effective when screening was linked with mandatory intervention or referral.
Conclusions
Screening for distress potentially has added value but at a cost of clinician time. Barriers to screening must be addressed for screening to be fully effective.
Mitchell AJ, Vaze A, Rao, S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009; 374, Issue 9690: 609 – 619.
Maria Hewitt, Julia H. Rowland Mental Health Service Use Among Adult Cancer Survivors: Analyses of the National Health Interview Survey Journal of Clinical Oncology, Vol 20, Issue 23 (December), 2002: 4581-4590
From the National Cancer Policy Board, Institute of Medicine, Washington,
DC, and Office of Cancer Survivorship, National Cancer Institute,
National Institutes of Health, Bethesda, MD.